Ultragenyx announced another round of workforce reductions alongside asset cuts aimed at halving R&D spend, according to the report. The company plans to lay off 20% of employees and scrap a Wilson disease gene therapy program as it adjusts its portfolio following a period that included FDA approvals but also a major clinical setback in Angelman syndrome. The move signals ongoing cost discipline in gene and rare disease categories as companies balance late-stage momentum with the reality of development risk and capital efficiency.